Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA.
Bioanalysis. 2024 Apr;16(7):165-177. doi: 10.4155/bio-2023-0261. Epub 2024 Feb 13.
Implementation of immunocapture LC-MS methods to characterize the pharmacokinetic profile of large molecule drugs has become a widely used technique over the past decade. As the pharmaceutical industry strives for speediness into clinical development without jeopardizing quality, robust assays with generic application across the pipeline are becoming instrumental in bioanalysis, especially in early-stage development. This review highlights the capabilities and challenges involved in hybrid immunocapture LC-MS techniques and its continued applications in nonclinical and clinical pharmacokinetic assay design. This includes a comparison of LC-MS-based approaches to conventional ligand-binding assays and the driving demands in large molecule drug portfolios including growing sensitivity requirements and the unique challenges of new modalities requiring innovation in the bioanalytical laboratory.
在过去十年中,免疫捕获 LC-MS 方法在表征大分子量药物的药代动力学特征方面的应用已经变得非常广泛。随着制药行业在不影响质量的前提下努力加快临床开发速度,具有通用性的强大分析方法在生物分析中变得越来越重要,尤其是在早期开发阶段。本文综述了混合免疫捕获 LC-MS 技术的特点和面临的挑战及其在非临床和临床药代动力学分析方法设计中的应用。这包括比较基于 LC-MS 的方法与传统配体结合分析方法,以及在大分子药物组合中不断增长的灵敏度要求和新方法所带来的独特挑战等方面的需求,这需要在生物分析实验室进行创新。